Cinda Biotech (01801): Daboxin® (ipimumab N01 injection) was approved by the State Drug Administration in conjunction with cindilizumab for new adjuvant treatment of colon cancer

Zhitongcaijing · 1d ago

Zhitong Finance App News, Cinda Biotech (01801) announced that daboxin ® (ipimumab N01 injection, cytotoxic T lymphocyte-related protein 4 (CTLA-4) monoclonal antibody (mAb), R&D code: IBI310) was approved for listing by the China National Drug Administration (NMPA), in combination with cindilizumab for operatively resectable phase IIB-III microsatellites highly unstable (MSI-H) or mismatched repair defective (dMMR) colon cancer patients . Daboxin ® (ipimumab N01 injection) is the first domestically produced anti-CTLA-4 monoclonal antibody approved in China, and the world's first anti-CTLA-4 monoclonal antibody approved for new adjuvant treatment of colon cancer. Through short-term new adjuvant treatment with cindilizumab, it can significantly improve the complete pathologic remission rate and benefit MSI-H/ dMMR colon cancer patients.